GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on March 02, 2026.
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
GlaxoSmithKline Pharmaceuticals announced a change in its Chief Financial Officer following a board meeting on March 2, 2026. Mr. Ronojit Biswas (DIN 07684843) has been appointed as the new Whole-Time Director & CFO for a 3-year term starting April 1, 2026. He brings over 25 years of experience with GSK across India, Vietnam, Singapore, Brazil, and the UK, and most recently served as Senior Finance Director – Global Product Strategy based in Singapore. The current CFO, Mr. Juby Chandy, will step down from his role effective March 11, 2026, to take on a new role leading APAC Finance within the GSK Group.
This is a smooth internal succession within the GSK Group with no immediate financial or operational impact expected. The appointment of a long-tenured GSK insider as CFO signals continuity in financial strategy and governance for shareholders.